Experts Press FDA for Clear Safety and Access Rules on Psychedelic Therapies (2026-09-17)

Doctors, veterans, pharmacists and therapists used a four-hour public meeting on Monday to press the U.S. Food and Drug Administration to set clear safety and access standards for psychedelic therapies, as the agency works to accelerate their development.

The hearing forms part of a months-long push begun by U.S. President Donald Trump's administration in April to bring qualified psychedelic drug programs to market.

Much of the discussion centred on practical questions that will shape how such treatments are tested and delivered: the training and credentials required of providers, how patients are screened and monitored, reimbursement and access, clinic capacity, and the gathering of long-term safety data.

Experts said any approved treatment would need trained staff present in the room during sessions that can run from six to 12 hours, along with proper screening, follow-up care and community support.

Speakers also called on researchers to record data on menstrual phases, pregnancy and postpartum status, perimenopause, menopause, hormonal status and concomitant medications. They warned that pooled results could hide differences in how well a treatment works or in the side effects patients experience.

"Important safety and treatment signals should not disappear inside population averages," said Melissa Lavasani, CEO of the Psychedelic Medicine Coalition.

The experts noted that treatments could remain out of reach without insurance coverage, adding that inadequate reimbursement for providers would leave clinics either serving mainly wealthy patients or struggling to stay afloat.

"Approval alone is not access. A breakthrough therapy nobody can reach is not a breakthrough — it is a press release," said Amna Aslam, applied research specialist at Radial Health.

An FDA framework

Days before the hearing, senior FDA officials, including Michael Davis, who heads the agency's Center for Drug Evaluation and Research, published a paper in the New England Journal of Medicine setting out a framework for developing and approving psychedelic drugs.

The officials said the agency was "meeting this moment" on hard-to-treat conditions such as major depressive disorder and PTSD.

According to Jefferies analysts, the framework signalled that the FDA was open to flexible trial designs to tackle challenges such as "functional unblinding," which occurs when a drug's noticeable psychoactive effects make clear to participants which treatment they received.

The administration's backing has renewed investor interest in the sector. Industry executives said it could improve coordination between the FDA and the Drug Enforcement Administration and help cut regulatory delays, though treatments are still likely years away.

The American Psychiatric Association said the FDA's determination of safety and effectiveness "must remain the foundation for any future clinical use."

Analysts said agreement among regulators, clinicians and developers on a safe, supervised rollout should benefit AtaiBeckley, Compass Pathways, Definium Therapeutics, Helus Pharma and GH Research.

"The science continues to advance, and continued thoughtful engagement among regulators, researchers and clinicians is critical to advancing these promising new treatments," said Helus CEO Michael Halstead.